Label Revisions Ordered for Evenity, Other Bone Disease Drugs

July 21, 2021
The Ministry of Health, Labor and Welfare (MHLW) on July 20 ordered label revisions to add new side effect risks for a group of treatments for bone diseases including Astellas Pharma’s osteoporosis treatment Evenity (romosozumab). The bone disease drugs subject...read more